The combination of docetaxel and cisplatin outperforms the standard first-line regimen of vinorelbine and cisplatin, showing significant survival advantage as first-line treatment for advanced non-small cell lung cancer, according to dramatic results from a pivotal phase III clinical trial presented at the 2001 Annual Meeting of the American Society of Clinical Oncology held in San Francisco on May 12 to 15, 2001.
Go to Previous Page
Go to Next Page